Ambalal Sarabhai Enterprises Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2012 • Pharmaceuticals: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company comfortably covers its interest (25.4x coverage)
- Company maintains a comfortable, low leverage position
CONS
- Company is loss-making at the operating / net level
- A large part of profit comes from other income (156.5% of PBT)
- Recent results are weak - TTM profit is down 51.4% versus prior year
- Operating cash flow has been negative in recent years
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.37x)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| AMBALALSA | 40.61 | 22.96 | 311.21 | 0.00 | 3.98 | -51.65 | 43.56 | 7.99 | 11.52 | 11.42 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 1 | 0 | 2 | 1 | |
| 5 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 2 | 1 | 3 | 2 | |
| Operating Profit | -3 | -1 | -2 | -1 | -1 | -2 | -3 | -2 | -1 | -2 | -1 | -1 | -1 |
| OPM % | -185.29% | -166.25% | -490.91% | -65.66% | -110.53% | — | -220.51% | -98.27% | -71.95% | -206.33% | — | -88.82% | -259.37% |
| 1 | 2 | 1 | 3 | 2 | 6 | 11 | -3 | 8 | 1 | 3 | 3 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before Tax | -2 | 1 | -0 | 3 | 0 | 4 | 8 | -5 | 7 | -0 | 2 | 2 | 0 |
| Tax % | -0.00% | 0.00% | -69.23% | -76.69% | 6.12% | 3.36% | -3.94% | 0.40% | 0.00% | -0.00% | -0.55% | -64.60% | 89.51% |
| Net Profit | -2 | 1 | -1 | 5 | 0 | 4 | 8 | -5 | 7 | -0 | 2 | 3 | 0 |
| -0.26 | 0.07 | -0.08 | 0.62 | 0.06 | 0.56 | 1.10 | -0.64 | 0.90 | -0.05 | 0.24 | 0.35 | 0.00 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 3 | |
| 22 | 22 | 9 | 8 | 38 | 6 | 9 | 9 | 11 | 9 | 8 | |
| Operating Profit | -21 | -21 | -9 | -8 | -38 | -6 | -5 | -5 | -7 | -5 | -5 |
| OPM % | -1364.41% | -2256.10% | — | — | — | -4366.12% | -139.11% | -125.83% | -181.30% | -129.87% | -186.79% |
| 7 | 24 | 6 | 25 | 30 | 9 | 10 | 8 | 16 | 16 | 9 | |
| Interest | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 1 |
| Depreciation | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before Tax | -19 | 2 | -3 | 16 | -9 | 3 | 4 | 1 | 8 | 10 | 3 |
| Tax % | -10.19% | 165.77% | -13.31% | 2.23% | 0.86% | 14.37% | 5.21% | -217.15% | -2.03% | -10.46% | -23.73% |
| Net Profit | -21 | -1 | -4 | 16 | -9 | 3 | 4 | 3 | 8 | 11 | 4 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -1.22 | 0.39 | 0.54 | 0.34 | 1.08 | 1.43 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- -6%
- 5 Years:
- —
- 3 Years:
- 2%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- -13%
- 5 Years:
- —
- 3 Years:
- 39%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- 2%
- 5 Years:
- 13%
- 3 Years:
- 15%
- Last Year:
- 20%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
| -46 | -48 | -52 | -36 | -46 | -43 | -39 | -36 | -28 | -17 | |
| 22 | 11 | 11 | 11 | 11 | 10 | 11 | 10 | 8 | 10 | |
| Trade Payables | 11 | 21 | 20 | 19 | 18 | 17 | 16 | 16 | 15 | 8 |
| 50 | 68 | 80 | 53 | 38 | 21 | 13 | 14 | 11 | 8 | |
| Total Liabilities | 113 | 128 | 136 | 123 | 98 | 82 | 78 | 80 | 82 | 85 |
| 16 | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 12 | 12 | |
| 76 | 67 | 67 | 65 | 35 | 26 | 26 | 25 | 25 | 25 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Bank | 5 | 6 | 4 | 4 | 9 | 5 | 3 | 3 | 3 | 4 |
| 16 | 40 | 50 | 39 | 40 | 38 | 37 | 39 | 41 | 43 | |
| Total Assets | 113 | 128 | 136 | 123 | 98 | 82 | 78 | 80 | 82 | 85 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -3 | 5 | 1 | -4 | -10 | -7 | 2 | -4 | -4 | -0 | |
| Cash from Investing | 9 | 26 | 2 | 5 | 16 | 21 | 1 | 3 | 6 | -3 |
| Cash from Financing | -8 | -12 | -0 | -0 | -0 | -16 | -4 | 0 | -2 | 3 |
| -3 | 1 | -1 | -0 | 5 | -3 | -2 | -0 | -0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for AMBALALSA
Loading news…
AI Stock Analyst
Ambalal Sarabhai Enterprises Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account